Senolytics and Eye Health: AMD, Glaucoma, and Retinal Senescence
Expert Summary
Retinal pigment epithelium cells accumulate oxidative damage from lifetime light exposure, driving senescent phenotypes by age 60–70. Senescent RPE cells produce VEGF (driving choroidal neovascularization in wet AMD), reduce photoreceptor nutrient support, and accumulate drusen-forming lipofuscin. Senolytic clearance of aged RPE cells is an active area of research.
Key Facts
- RPE senescence in AMD: In AMD retinal tissue, 60–70% of RPE cells show senescence markers (SA-β-Gal, p16) compared to 20–30% in age-matched non-AMD tissue. Senescent RPE cells reduce rhodopsin recycling, impair photoreceptor survival, and produce SASP that drives chronic drusen accumulation.
- Drusen and SASP: Drusen (lipid-protein deposits beneath the RPE) are partly composed of SASP-related complement proteins and oxidized lipoproteins from senescent RPE cells. Reducing senescent RPE burden may slow drusen accumulation.
- Glaucoma and trabecular meshwork: Trabecular meshwork (TM) cells regulate intraocular pressure (IOP). Senescent TM cells lose their filtration function and secrete SASP that further impairs TM health — driving IOP elevation in primary open-angle glaucoma.
- Fisetin for retina: Fisetin's documented neuroprotective and antioxidant effects in neural tissue extend to retinal models. Fisetin reduces oxidative stress-induced RPE senescence in cell culture and protects photoreceptor function.
- Quercetin and eye: Quercetin's antioxidant activity in lens epithelial cells reduces protein glycation and oxidative damage — relevant for cataract prevention alongside its senolytic activity.
Recommended Products
Frequently Asked Questions
Can senolytics prevent AMD?
No confirmed human evidence exists for AMD prevention by senolytics. The mechanistic rationale (RPE senescence drives AMD) is strong, and preclinical data is promising. AMD prevention trials with senolytics are a logical next step but have not been completed.
Do senolytics lower intraocular pressure in glaucoma?
No direct human evidence. Animal models show trabecular meshwork function improvement post-senolytic treatment. Human glaucoma patients considering senolytics should maintain standard treatments.
Scientific References
- Sreekumar PG et al. Mitochondrial dysfunction and cell senescence: cause or consequence in age-related macular degeneration. Redox Biology. 2021.